news

CUPERTINO, Calif., Nov. 26 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at the following upcoming healthcare conferences in New York, NY. — 20th Annual Piper Jaffray Health Care Conference on Wednesday, December 3rd at 8:00 a.m. Eastern Time. — RBC Capital Markets 2008 Healthcare Conference on Wednesday, December […]

CUPERTINO, Calif., Nov. 3 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2008. Total revenues were $6.6 million for the three months ended September 30, 2008, compared to $4.9 million for the same period in 2007. Net loss for the three months ended September 30, 2008

CUPERTINO, Calif., Oct. 29 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that the previously announced development and license agreement with Alpharma Ireland Limited, an affiliate of Alpharma Inc. (NYSE: ALO), granting such party the exclusive worldwide rights to develop and commercialize ELADUR(TM), DURECT’s investigational transdermal bupivacaine patch, has cleared review under the Hart-Scott-Rodino (HSR)

CUPERTINO, Calif., Oct. 28 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at the following upcoming healthcare conferences in New York, NY. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) — Oppenheimer 19th Annual Healthcare Conference on Tuesday, November 4th at 3:20 p.m. Eastern Time. — Barclays Capital Small & Mid-Cap Healthcare Forum on Thursday,

CUPERTINO, Calif., Oct. 27 /PRNewswire-FirstCall/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) third quarter 2008 financial results press release, you are invited to listen to the conference call that will be broadcast live over the Internet on Monday, November 3, 2008 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) A live

CUPERTINO, Calif., Sept. 22 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it has entered into a development and license agreement with an affiliate of Alpharma Inc. (NYSE: ALO) granting such party the exclusive worldwide rights to develop and commercialize ELADUR(TM), DURECT’s investigational transdermal bupivacaine patch currently under development for the treatment of pain

CUPERTINO, Calif., Sept. 15 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the 2008 UBS Global Life Sciences Conference being held at the Grand Hyatt Hotel in New York. Matthew J. Hogan, Chief Financial Officer, will be presenting at the conference on September 22 at 10:30 a.m. Eastern Time. (Logo:

CUPERTINO, Calif., Aug 27, 2008 /PRNewswire-FirstCall via COMTEX News Network/ — DURECT Corporation (Nasdaq: DRRX) today reported that Pain Therapeutics (Nasdaq: PTIE), its licensee, has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for an abuse-resistant opioid pain drug candidate based on DURECT’s patented ORADUR(TM) technology. This is

CUPERTINO, Calif., Aug. 12 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that the US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) of REMOXY(R) and granted Priority Review. The FDA typically grants Priority Review to drug candidates that have the potential to demonstrate significant improvements compared to marketed products. The

CUPERTINO, Calif., Aug. 5 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2008. Total revenues were $6.3 million for the three months ended June 30, 2008, compared to $13.4 million for the same period in 2007. Net loss for the three months ended June 30, 2008